Bifidobacterium breve VPro 52 and Reduced Incidence of NEC Stage II or Greater

• Outcomes in preterm small versus appropriate for gestation infants after Bifidobacterium breve M-16 V supplementation

  • 2018-11-22
  • Observational · n = 1,380
  • The Journal of Maternal-Fetal & Neonatal Medicine 33(13)
  • • G. Athalye-Jape
    • N. Minaee
    • E. Nathan
    • K. Simmer
    • S. Patole

  • PubMed: 30394171
  • DOI: 10.1080/14767058.2018.1543657

  11 Insights on

  • Reduced Incidence of NEC Stage II or Greater

  • High evidence

  Primary outcome 'NEC ≥ Stage II /all-cause mortality' was higher in SGA versus AGA infants <29 weeks (21 versus 12%; *p* = .040), and showed trend toward reduction (8 versus 6%; *p* = .057) in AGA <34 weeks.

  Effect

  Neutral

  Effect size

  Small

  Significant

  Yes